| PROGRAM/TARGET | INDICATION | DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|---|---|
| ZE46-0134 FLT3/IRAK4 |
Healthy Volunteer Study | |||||
| AML | ||||||
| ZE50-0134 BCL2 | CLL | |||||
| AML | ||||||
| ZE63-0302 Menin |
AML | |||||
| Undisclosed | ||||||
| Undisclosed | ||||||
| Undisclosed | ||||||
| PROGRAM/TARGET | INDICATION | DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|---|---|
| ZE46-0134 FLT3/IRAK4 |
Healthy Volunteer Study | |||||
| AML | ||||||
| ZE50-0134 BCL2 | CLL | |||||
| AML | ||||||
| ZE63-0302 Menin |
AML | |||||
| Undisclosed | ||||||
| Undisclosed | ||||||
| Undisclosed | ||||||